Delving into the Strategies to Effectively Measure AAV Safety in the Liver when AAV Gene Therapies are Administered Systemically & Intra CSF
Time: 10:00 am
day: Day Two
Details:
• Assessing the importance of the correct patient population to avoid the risk of decompensation
• Leveraging liver biopsies to understand which cells are infiltrating the liver to gain more mechanistic understanding
• Integrating novel monitoring methods to explore where the liver damage has occurred
• Exploring the analysis of red cell morphology to inform on the overall safety profile of AAV